2.The Impact of Aerobic Training on Exercise Tolerance and Obstructive Sleep Apnoea (OSA) in Obese People
Manoranjitham R ; Ishwarya Vardhini C ; Thiruppathi A ; Deepa I ; Saraswathi K
Malaysian Journal of Medicine and Health Sciences 2026;22(No. 1):1-5
Introduction: Obstructive sleep apnoea (OSA) is characterised by recurrent pharyngeal collapses that occur five or more times per hour of sleep or more and reduce or completely block airflow for at least 10 seconds. Obesity predis-poses individuals to and potentiates OSA. Materials and methods: As a pre- and post-training activity measure, 30 obese people between the ages of 25 and 45 were asked to complete the STOP-BANG questionnaire and a 6-minute walk test. After that, they engaged in aerobic activity. Results: The scores for the six-minute walk test and the stop-bang questionnaire were 0.0005 and 0.0003, respectively with a “p” value- ≤0.001 (significant). In our investigation, the effects of aerobic exercise on exercise tolerance and obstructive sleep apnoea were significantly different. Con-clusion: Aerobic exercise is a better intervention for increasing exercise tolerance and obstructive sleep apnoea in obese patients. This intervention may be a significant contributor to cardiorespiratory fitness and can be considered a useful tool for enhancing quality of life.
3.Expert Opinion on the Management of Hyperkalemia in Patients with Cardiorenal Diseases Treated with Renin Angiotensin Aldosterone System Inhibitors: An Indonesian Perspective
Pringgodigdo Nugroho ; Aida Lydia ; Haerani Abdul Rasyid ; Zulkhair Ali ; Pranawa Pranawa ; Nyoman Paramita Ayu ; Birry Karim ; Erwin Sukandi ; Siti Elkana Nauli ; Hary Sakti Muliawan ; Edrian Zulkarnain
Acta Medica Indonesiana 2026;58(1):123-132
Abstract
Hyperkalemia (serum potassium >5.0 mEq/l) is a significant complication in patients with heart failure, chronic kidney disease, and diabetes mellitus, particularly when treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Both hyperkalemia and RAASi interruption are associated with increased cardiovascular events, hospitalizations, and mortality. This expert opinion document, developed between January and December 2024 through a systematic process, aims to establish guidance for hyperkalemia treatment in Indonesian patients with cardiorenal diseases receiving RAASi therapy, addressing the unique challenges within the Indonesian healthcare context. A comprehensive literature review of international guidelines and regional studies was conducted by a panel of 11 expert specialists (3 cardiologists, 6 internist-nephrologists, and 2 internist-cardiologists), who evaluated 29 statements covering diagnosis, monitoring, prevention, and treatment of hyperkalemia. Of the 29 statements, 26 reached consensus: 17 statements achieved very high agreement (≥90%) and 9 attained high agreement (≥67% – <90%). The agreed statements covered key areas, including potassium monitoring frequency, RAASi dose optimization strategies, dietary modifications, and treatment thresholds. Three statements regarding alternative therapeutic approaches did not receive agreement (<67%) due to limited local availability and cost considerations. Key recommendations include structured monitoring protocols for high-risk patients, strategies for RAASi dose optimization while managing hyperkalemia risk, and specific interventions adapted to local resources. This document provides a practical approach for managing hyperkalemia in Indonesian patients with cardiorenal diseases while maintaining optimal RAASi therapy, considering local Indonesian healthcare resources and constraints.
Hyperkalemia
;
Cardio-Renal Syndrome
;
Renin-Angiotensin System
;
Indonesia
4.Ending nuclear weapons, before they end us
Kamran Abbasi ; Parveen Ali ; Virginia Barbour ; Marion Birch ; Inga Blum ; Peter Doherty ; Andy Haines ; Ira Helfand ; Richard Horton ; Kati Juva ; José ; Florencio F. Lapeñ ; a, Jr. ; Robert Mash ; Olga Mironova ; Arun Mitra ; Carlos Monteiro ; Elena N. Naumova ; David Onazi ; Tilman Ruff ; Peush Sahni ; James Tumwine ; Carlos Umañ ; a ; Paul Yonga ; Joe Thomas ; Chris Zielinski
Philippine Journal of Otolaryngology Head and Neck Surgery 2025;40(1):6-8
5.Testicular tumours in children: a single-centre experience.
Sajid ALI ; Tariq LATIF ; Muhammad Ali SHEIKH ; Shazia PERVEEN ; Muhammad BILAL ; Albash SARWAR
Singapore medical journal 2025;66(6):321-326
INTRODUCTION:
Testicular tumours in childhood have diverse characteristics for different age ranges. This study aimed to describe the pattern, presentation and outcomes of primary testicular tumours in a paediatric population.
METHODS:
A retrospective study was conducted from January 2010 to December 2020 on children (≤18 years) with a diagnosis of primary testicular tumour. Baseline demographics, clinical characteristics, pathology, treatment and outcomes of these patients were analysed. The data were entered into IBM SPSS Statistics version 20.0. Chi-square test and Fisher's exact test were applied to find the statistical significance, which was set at P value ≤ 0.05.
RESULTS:
The study included 115 males, with 85 (73.9%) patients in the prepubertal age range with a mean age of 2.53 ± 2.06 years and 30 (26.1%) patients in the postpubertal group with a mean age of 15.73 ± 1.25 years. Yolk sac tumour was the most common (62.6%) histological subtype. Majority (46.1%) of patients had stage I disease on presentation, while 29.6% had stage IV disease. All patients underwent upfront high inguinal radical orchiectomy, which was followed by platinum-based adjuvant chemotherapy in 67% of the patients. The five-year event-free survival and overall survival for all patients were 75% and 91%, respectively.
CONCLUSION
Primary testicular tumours follow a bimodal age distribution pattern. Majority of patients can be cured with platinum-based chemotherapy despite having advanced disease at presentation.
Humans
;
Male
;
Testicular Neoplasms/mortality*
;
Retrospective Studies
;
Adolescent
;
Child
;
Child, Preschool
;
Orchiectomy/methods*
;
Chemotherapy, Adjuvant
;
Treatment Outcome
;
Neoplasm Staging
;
Infant
;
Endodermal Sinus Tumor/therapy*
;
Neoplasms, Germ Cell and Embryonal
6.Engineering and targeting potential of CAR NK cells in colorectal cancer.
Muhammad Babar KHAWAR ; Ali AFZAL ; Shuangshuang DONG ; Yue SI ; Haibo SUN
Chinese Medical Journal 2025;138(13):1529-1539
Colorectal cancer (CRC), a major global health concern, necessitates innovative treatments. Chimeric antigen receptor (CAR) T cells have shown promises, yet they grapple with challenges. The spotlight pivots to the rising heroes: CAR natural killer (NK) cells, offering advantages such as higher safety profiles, cost-effectiveness, and efficacy against solid tumors. Nevertheless, the specific mechanisms underlying CAR NK cell trafficking and their interplay within the complex tumor microenvironment require further in-depth exploration. Herein, we provide insights into the design and engineering of CAR NK cells, antigen targets in CRC, and success in overcoming resistance mechanisms with an emphasis on the potential for clinical trials.
Colorectal Neoplasms/immunology*
;
Humans
;
Killer Cells, Natural/metabolism*
;
Receptors, Chimeric Antigen/genetics*
;
Immunotherapy, Adoptive/methods*
;
Tumor Microenvironment/immunology*
;
Animals
7.Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.
Ali A ALSHAHRANI ; Evangelos KONTOPANTELIS ; Catharine MORGAN ; Rathi RAVINDRARAJAH ; Glen P MARTIN ; Mamas A MAMAS
Chinese Medical Journal 2025;138(2):143-154
This article provides an overview of the current evidence on the epidemiology, overlapping risk factors, and pathophysiology of cardiovascular disease (CVD) in patients with cancer. It explores the cardiotoxic effects of anticancer therapy and their impact on prognosis. Although cancer survival rates have improved over the last two decades, the risk of CVD has risen over time in patients with cancer. CVD and cancer share similar risk factors and a common pathophysiology involving inflammation. Many chemotherapeutic agents used to treat cancer are associated with cardiovascular complications (such as heart failure, myocardial infarction, and thrombosis). Current evidence indicates a significant burden of CVD in patients with cancer, particularly in the first year following cancer diagnosis, with elevated risk persisting beyond this period. This short- and long-term risk of CVD may vary depending on the cancer type and treatment regimen. Early identification of potential cardiovascular risk in patients with cancer, can lead to more favorable clinical and survival outcomes. Given the acute and long-term consequences, patients with cancer require increased cardiovascular care and lifestyle optimization. This article offers valuable insights into the cardiovascular burden and needs of patients with cancer. It is intended for a general medical research readership interested in the intersection of cardiology and oncology.
Humans
;
Neoplasms/drug therapy*
;
Cardiovascular Diseases/etiology*
;
Prognosis
;
Risk Factors
;
Antineoplastic Agents/therapeutic use*
9.Effects of Acupuncture on Cognitive Functions in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.
Faezeh KHODAIE ; Roghayyeh SAEEDI ; Ghazaleh SOLEIMANY ; Mohammad Ali SAHRAIAN ; Amir Hooman KAZEMI ; Abdorreza Naser MOGHADASI ; Bai-Xiao ZHAO
Chinese journal of integrative medicine 2025;31(10):928-936
OBJECTIVE:
To explore the effects of acupuncture in comparison with sham acupuncture on cognitive functions in patients with relapsing-remitting multiple sclerosis (RRMS).
METHODS:
In this randomized controlled trial, 31 RRMS patients in the acupuncture group were treated with traditional Chinese acupuncture based on the treatment principle of calming the mind, reinforcing qi and blood, and 31 patients in the control group were treated with sham acupuncture (shallow needling at non-acupuncture points) twice a week for 12 weeks. The primary outcome was the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) score, which was evaluated by a psychologist at baseline and after 12 weeks of treatment. The secondary outcomes were the Symptom Checklist 90-Revised (SCL-90-R), Pittsburgh Sleep Quality Index (PSQI), and Fatigue Severity Scale (FSS) scores. The participants were provided with contact information from the researchers with constant access to report any adverse symptoms.
RESULTS:
In total, 62 participants were enrolled and allocated to the acupuncture group (31 cases) or control group (31 cases). After 12 weeks of acupuncture treatment, BICAMS including Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-2 (CVLT-2) and delayed CVLT-2 scores were significantly improved in comparison with the control group (P<0.01). However, the changes in the Brief Visuospatial Memory Test-Revised (BVMT-R) and delayed BVMT-R scores related to visual/spatial memory did not differ significantly between the two groups (both P>0.05). The FSS, PSQI, and SCL-90-R scores were significantly reduced after 12-week treatment in the acupuncture group compared to the control group (P<0.05 or P<0.01). No life-threatening adverse events occurred throughout the study.
CONCLUSIONS
Twelve weeks of acupuncture treatment was effective in improving immediate and short-term auditory/verbal memory, attention and processing speed; reducing fatigue and decreasing sleep latency and the use of sleeping medications; alleviating depression, somatization, obsessive-compulsive and paranoid disorders in patients with RRMS. (Iranian Registry of Clinical Trials, No. IRCT20220101053582N1).
Humans
;
Multiple Sclerosis, Relapsing-Remitting/physiopathology*
;
Acupuncture Therapy
;
Female
;
Male
;
Cognition/physiology*
;
Adult
;
Treatment Outcome
;
Middle Aged
10.Potential effect of endothelial progenitor cells on pentylenetetrazole-induced seizures in rats: an evaluation of relevant lncRNAs.
Shimaa O ALI ; Nancy N SHAHIN ; Marwa M SAFAR ; Sherine M RIZK
Journal of Zhejiang University. Science. B 2025;26(8):789-804
OBJECTIVES:
The use of stem cells is a promising strategy for seizure treatment owing to their unique characteristics. We investigated the role of endothelial progenitor cells (EPCs) in a pentylenetetrazole (PTZ)-induced rat seizure model. A selected panel of long noncoding RNAs (lncRNAs), which maintain an elaborate balance in brain neural regulatory networks as well as the autophagy pathway, was also targeted.
METHODS:
The impact of intravenously administered EPCs on PTZ-induced kindling in rats was evaluated by measuring the expression of neuronal damage markers, neurotrophic factors, and relevant lncRNA genes. Rat behavior was assessed using Y-maze test and open field test (OFT).
RESULTS:
EPCs mitigated seizure-associated neurological damage and reversed PTZ-induced working memory and locomotor activity deficits, as evidenced by improved performance in the Y-maze test and OFT. EPC treatment reversed the downregulation of the expression of the lncRNAs Evf2, Pnky, Dlx1, APF, HOTAIR, and FLJ11812. EPCs also boosted vascular endothelial growth factor (VEGF) expression. The ameliorative effect achieved by EPCs was comparable to that produced by valproate.
CONCLUSIONS
These findings indicate that EPCs ameliorate kindling epileptic seizures and their associated abnormalities and that the effect of EPCs may be mediated via the upregulation of certain regulatory lncRNAs.
Animals
;
Pentylenetetrazole
;
RNA, Long Noncoding
;
Seizures/therapy*
;
Rats
;
Male
;
Endothelial Progenitor Cells/transplantation*
;
Rats, Sprague-Dawley
;
Kindling, Neurologic
;
Vascular Endothelial Growth Factor A/metabolism*
;
Disease Models, Animal


Result Analysis
Print
Save
E-mail